Systemic and Local Administration of a Dual-siRNA Complex Efficiently Inhibits Tumor Growth and Bone Invasion in Oral Squamous Cell Carcinoma
Oral squamous cell carcinoma (OSCC) accounts for nearly 90% of oral and oropharyngeal cancer cases and is characterized by high mortality and poor prognosis. RNA-based gene therapies have been developed as an emerging option for cancer treatment, but it has not been widely explored in OSCC. In this...
Saved in:
Published in | Molecular pharmaceutics Vol. 21; no. 2; pp. 661 - 676 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Chemical Society
05.02.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Oral squamous cell carcinoma (OSCC) accounts for nearly 90% of oral and oropharyngeal cancer cases and is characterized by high mortality and poor prognosis. RNA-based gene therapies have been developed as an emerging option for cancer treatment, but it has not been widely explored in OSCC. In this work, we developed an efficient siRNA cationic micelle DOTAP-mPEG–PCL (DMP) by self-assembling the cationic lipid DOTAP and monomethoxy poly(ethylene glycol)-poly(ε-caprolactone) (mPEG–PCL) polymer. We tested the characteristics and transformation efficiency of this micelle and combined DMP with siRNA targeting STAT3 and TGF-β to evaluate the antitumor effect and bone invasion interfering in vitro and in vivo. The average size of the DMP was 28.27 ± 1.62 nm with an average zeta potential of 54.60 ± 0.29 mV. The DMP/siRNA complex showed high delivery efficiency, with rates of 97.47 ± 0.42% for HSC-3. In vitro, the DMP/siSTAT3 complex exhibited an obvious cell growth inhibition effect detected by MTT assay (an average cell viability of 25.1%) and clonogenic assay (an average inhibition rate of 51.9%). Besides, the supernatant from HSC-3 transfected by DMP/siTGF-β complexes was found to interfere with osteoclast differentiation in vitro. Irrespective of local or systemic administration, DMP/siSTAT3+siTGF-β showed antitumor effects and bone invasion inhibition in the OSCC mice mandibular invasion model according to tumor volume assays and Micro-CT scanning. The complex constructed by DMP cationic micelles and siSTAT3+siTGF-β represents a potential RNA-based gene therapy delivery system for OSCC. |
---|---|
AbstractList | Oral squamous cell carcinoma (OSCC) accounts for nearly 90% of oral and oropharyngeal cancer cases and is characterized by high mortality and poor prognosis. RNA-based gene therapies have been developed as an emerging option for cancer treatment, but it has not been widely explored in OSCC. In this work, we developed an efficient siRNA cationic micelle DOTAP-mPEG–PCL (DMP) by self-assembling the cationic lipid DOTAP and monomethoxy poly(ethylene glycol)-poly(ε-caprolactone) (mPEG–PCL) polymer. We tested the characteristics and transformation efficiency of this micelle and combined DMP with siRNA targeting STAT3 and TGF-β to evaluate the antitumor effect and bone invasion interfering in vitro and in vivo. The average size of the DMP was 28.27 ± 1.62 nm with an average zeta potential of 54.60 ± 0.29 mV. The DMP/siRNA complex showed high delivery efficiency, with rates of 97.47 ± 0.42% for HSC-3. In vitro, the DMP/siSTAT3 complex exhibited an obvious cell growth inhibition effect detected by MTT assay (an average cell viability of 25.1%) and clonogenic assay (an average inhibition rate of 51.9%). Besides, the supernatant from HSC-3 transfected by DMP/siTGF-β complexes was found to interfere with osteoclast differentiation in vitro. Irrespective of local or systemic administration, DMP/siSTAT3+siTGF-β showed antitumor effects and bone invasion inhibition in the OSCC mice mandibular invasion model according to tumor volume assays and Micro-CT scanning. The complex constructed by DMP cationic micelles and siSTAT3+siTGF-β represents a potential RNA-based gene therapy delivery system for OSCC. Oral squamous cell carcinoma (OSCC) accounts for nearly 90% of oral and oropharyngeal cancer cases and is characterized by high mortality and poor prognosis. RNA-based gene therapies have been developed as an emerging option for cancer treatment, but it has not been widely explored in OSCC. In this work, we developed an efficient siRNA cationic micelle DOTAP-mPEG-PCL (DMP) by self-assembling the cationic lipid DOTAP and monomethoxy poly(ethylene glycol)-poly(ε-caprolactone) (mPEG-PCL) polymer. We tested the characteristics and transformation efficiency of this micelle and combined DMP with siRNA targeting STAT3 and TGF-β to evaluate the antitumor effect and bone invasion interfering in vitro and in vivo. The average size of the DMP was 28.27 ± 1.62 nm with an average zeta potential of 54.60 ± 0.29 mV. The DMP/siRNA complex showed high delivery efficiency, with rates of 97.47 ± 0.42% for HSC-3. In vitro, the DMP/siSTAT3 complex exhibited an obvious cell growth inhibition effect detected by MTT assay (an average cell viability of 25.1%) and clonogenic assay (an average inhibition rate of 51.9%). Besides, the supernatant from HSC-3 transfected by DMP/siTGF-β complexes was found to interfere with osteoclast differentiation in vitro. Irrespective of local or systemic administration, DMP/siSTAT3+siTGF-β showed antitumor effects and bone invasion inhibition in the OSCC mice mandibular invasion model according to tumor volume assays and Micro-CT scanning. The complex constructed by DMP cationic micelles and siSTAT3+siTGF-β represents a potential RNA-based gene therapy delivery system for OSCC. Oral squamous cell carcinoma (OSCC) accounts for nearly 90% of oral and oropharyngeal cancer cases and is characterized by high mortality and poor prognosis. RNA-based gene therapies have been developed as an emerging option for cancer treatment, but it has not been widely explored in OSCC. In this work, we developed an efficient siRNA cationic micelle DOTAP-mPEG-PCL (DMP) by self-assembling the cationic lipid DOTAP and monomethoxy poly(ethylene glycol)-poly(ε-caprolactone) (mPEG-PCL) polymer. We tested the characteristics and transformation efficiency of this micelle and combined DMP with siRNA targeting STAT3 and TGF-β to evaluate the antitumor effect and bone invasion interfering and . The average size of the DMP was 28.27 ± 1.62 nm with an average zeta potential of 54.60 ± 0.29 mV. The DMP/siRNA complex showed high delivery efficiency, with rates of 97.47 ± 0.42% for HSC-3. , the DMP/siSTAT3 complex exhibited an obvious cell growth inhibition effect detected by MTT assay (an average cell viability of 25.1%) and clonogenic assay (an average inhibition rate of 51.9%). Besides, the supernatant from HSC-3 transfected by DMP/siTGF-β complexes was found to interfere with osteoclast differentiation . Irrespective of local or systemic administration, DMP/siSTAT3+siTGF-β showed antitumor effects and bone invasion inhibition in the OSCC mice mandibular invasion model according to tumor volume assays and Micro-CT scanning. The complex constructed by DMP cationic micelles and siSTAT3+siTGF-β represents a potential RNA-based gene therapy delivery system for OSCC. |
Author | Men, Yi He, Mingxia Gao, Yan Wu, Jieping Ma, Pingchuan Li, Chunjie Lian, Haosen Li, Jingmei Men, Ke |
AuthorAffiliation | State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology West China Hospital of Sichuan University Joint National Laboratory for Antibody Drug Engineering, School of Medicine State Key Laboratory of Biotherapy and Cancer Center |
AuthorAffiliation_xml | – name: West China Hospital of Sichuan University – name: State Key Laboratory of Biotherapy and Cancer Center – name: State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology – name: Joint National Laboratory for Antibody Drug Engineering, School of Medicine |
Author_xml | – sequence: 1 givenname: Pingchuan orcidid: 0000-0003-2298-7224 surname: Ma fullname: Ma, Pingchuan organization: State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology – sequence: 2 givenname: Mingxia surname: He fullname: He, Mingxia organization: Joint National Laboratory for Antibody Drug Engineering, School of Medicine – sequence: 3 givenname: Haosen surname: Lian fullname: Lian, Haosen organization: State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology – sequence: 4 givenname: Jingmei surname: Li fullname: Li, Jingmei organization: West China Hospital of Sichuan University – sequence: 5 givenname: Yan orcidid: 0000-0002-1933-724X surname: Gao fullname: Gao, Yan organization: West China Hospital of Sichuan University – sequence: 6 givenname: Jieping surname: Wu fullname: Wu, Jieping organization: West China Hospital of Sichuan University – sequence: 7 givenname: Ke orcidid: 0000-0002-0587-9961 surname: Men fullname: Men, Ke organization: West China Hospital of Sichuan University – sequence: 8 givenname: Yi surname: Men fullname: Men, Yi email: yurimen@163.com organization: State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology – sequence: 9 givenname: Chunjie surname: Li fullname: Li, Chunjie email: lichunjie07@qq.com organization: State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38175819$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkctu2zAQRYkiRfNof6Fgd93I4UMPaumqzgMwGqBJ18KYImEGIumQVBp_RP45dOwE6K6rITB3ztzhPUVHzjuF0DdKZpQweg4yzqwfN2sIFqSa0oxLQgRhH9AJrUpeCN6yo_e3KI_RaYz3hLCyYvwTOuaCNpWg7Ql6vt3GpKyRGNyAl17CiOeDNc7EFCAZ77DXGPDPCcYimt-_5rjzdjOqJ7zQ2kijXBq3-NqtzcqkiO8m6wO-DP5vWr8if2Truf0IcccyDt-EvOL2YQLrp4g7NY64gyCN8xY-o48axqi-HOoZ-nOxuOuuiuXN5XU3XxbAa54KWreCallRgEYKaAbFgNSiaVldgWxXVHG5kko0uqlJowYigNaaEQIV0SVn_Ax933M3wT9MKqbemiizFXAqu-pZy1hZNiUXWdrupTL4GIPS_SYYC2HbU9Lv0uhzGv0_afSHNPLs18OaaWXV8D759v1ZUO0FO8a9n4LLV_8H-AWPH6F7 |
CitedBy_id | crossref_primary_10_3390_ijms25105083 |
Cites_doi | 10.1111/j.1601-0825.2010.01781.x 10.1186/s12951-021-01088-9 10.1016/j.yexcr.2008.06.006 10.1002/smll.201802565 10.1166/jbn.2018.2593 10.2147/IJN.S357702 10.1002/advs.201900667 10.1038/bjc.2017.239 10.1021/acs.molpharmaceut.1c00461 10.3109/15412555.2013.813928 10.1016/j.oraloncology.2017.02.016 10.1016/j.pdpdt.2021.102581 10.1016/j.tranon.2021.101236 10.1016/j.canlet.2014.12.052 10.1016/j.oraloncology.2012.08.004 10.1111/jop.13268 10.1080/1061186X.2018.1502775 10.1158/1535-7163.MCT-11-0648 10.1166/jbn.2020.2961 10.1038/gt.2017.6 10.1016/j.biomaterials.2018.09.017 10.1007/s10555-011-9335-7 10.1002/jgm.3097 10.1111/cbdd.12993 10.1039/C7RA13656K 10.1097/CJI.0000000000000166 10.1186/1471-2407-13-605 10.1172/JCI125336 10.2174/0929867328666201207202012 10.1016/j.bbrc.2015.02.013 10.1038/nrclinonc.2018.8 10.3109/1061186X.2015.1070856 10.1080/14712598.2020.1738377 10.1016/j.bbrc.2020.11.073 10.1016/j.jconrel.2012.01.045 10.1021/acs.nanolett.7b01571 10.7150/thno.45164 10.1038/s41556-021-00641-w 10.3390/cancers12071889 10.2147/IJN.S277845 10.3892/mmr.2017.7625 10.1126/sciadv.aay3324 10.3322/caac.21492 10.1039/c2nr30079f 10.1016/j.semcancer.2018.01.008 10.4317/medoral.18772 10.1016/j.jconrel.2012.05.005 10.1016/j.ebiom.2019.08.013 10.1016/j.bone.2008.03.026 10.1038/s41467-022-31475-1 10.1002/ijc.33579 |
ContentType | Journal Article |
Copyright | 2024 American Chemical Society |
Copyright_xml | – notice: 2024 American Chemical Society |
DBID | NPM AAYXX CITATION 7X8 |
DOI | 10.1021/acs.molpharmaceut.3c00802 |
DatabaseName | PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1543-8392 |
EndPage | 676 |
ExternalDocumentID | 10_1021_acs_molpharmaceut_3c00802 38175819 a103371425 |
Genre | Journal Article |
GroupedDBID | --- -~X 123 4.4 53G 55A 5VS 7~N AABXI ABFRP ABJNI ABMVS ABQRX ABUCX ACGFS ACS ADHLV AEESW AENEX AFEFF AHGAQ ALMA_UNASSIGNED_HOLDINGS AQSVZ CS3 DU5 EBS ED~ F5P GGK GNL H~9 IH9 JG~ P2P RNS ROL UI2 VF5 VG9 W1F BAANH CUPRZ NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-a363t-16981fc51aa7c8a7de2a06879265ac9b1e3cbce87f7607ed08a16f200a50f4323 |
IEDL.DBID | ACS |
ISSN | 1543-8384 |
IngestDate | Fri Aug 16 20:37:15 EDT 2024 Fri Aug 23 01:51:39 EDT 2024 Sat Nov 02 12:11:04 EDT 2024 Tue Feb 06 03:15:53 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | siRNA delivery gene therapy oral squamous cell carcinoma bone invasion |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a363t-16981fc51aa7c8a7de2a06879265ac9b1e3cbce87f7607ed08a16f200a50f4323 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-0587-9961 0000-0003-2298-7224 0000-0002-1933-724X |
PMID | 38175819 |
PQID | 2922447438 |
PQPubID | 23479 |
PageCount | 16 |
ParticipantIDs | proquest_miscellaneous_2922447438 crossref_primary_10_1021_acs_molpharmaceut_3c00802 pubmed_primary_38175819 acs_journals_10_1021_acs_molpharmaceut_3c00802 |
PublicationCentury | 2000 |
PublicationDate | 2024-02-05 |
PublicationDateYYYYMMDD | 2024-02-05 |
PublicationDate_xml | – month: 02 year: 2024 text: 2024-02-05 day: 05 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Molecular pharmaceutics |
PublicationTitleAlternate | Mol. Pharmaceutics |
PublicationYear | 2024 |
Publisher | American Chemical Society |
Publisher_xml | – name: American Chemical Society |
References | ref9/cit9 ref45/cit45 ref3/cit3 ref27/cit27 ref16/cit16 ref23/cit23 ref8/cit8 ref31/cit31 ref2/cit2 ref34/cit34 ref37/cit37 ref20/cit20 ref48/cit48 ref17/cit17 ref10/cit10 ref35/cit35 ref19/cit19 ref21/cit21 ref42/cit42 ref46/cit46 ref49/cit49 ref13/cit13 ref24/cit24 ref38/cit38 ref50/cit50 ref6/cit6 ref36/cit36 ref18/cit18 ref11/cit11 ref25/cit25 ref29/cit29 ref32/cit32 ref39/cit39 ref14/cit14 ref5/cit5 ref51/cit51 ref43/cit43 ref28/cit28 ref40/cit40 ref26/cit26 ref12/cit12 ref15/cit15 ref41/cit41 ref22/cit22 ref33/cit33 ref4/cit4 ref30/cit30 ref47/cit47 ref1/cit1 ref44/cit44 ref7/cit7 |
References_xml | – ident: ref8/cit8 doi: 10.1111/j.1601-0825.2010.01781.x – ident: ref12/cit12 doi: 10.1186/s12951-021-01088-9 – ident: ref18/cit18 doi: 10.1016/j.yexcr.2008.06.006 – ident: ref42/cit42 doi: 10.1002/smll.201802565 – ident: ref31/cit31 doi: 10.1166/jbn.2018.2593 – ident: ref32/cit32 doi: 10.2147/IJN.S357702 – ident: ref2/cit2 doi: 10.1002/advs.201900667 – ident: ref6/cit6 doi: 10.1038/bjc.2017.239 – ident: ref33/cit33 doi: 10.1021/acs.molpharmaceut.1c00461 – ident: ref10/cit10 doi: 10.3109/15412555.2013.813928 – ident: ref38/cit38 doi: 10.1016/j.oraloncology.2017.02.016 – ident: ref39/cit39 doi: 10.1016/j.pdpdt.2021.102581 – ident: ref19/cit19 doi: 10.1016/j.tranon.2021.101236 – ident: ref40/cit40 doi: 10.1016/j.canlet.2014.12.052 – ident: ref9/cit9 doi: 10.1016/j.oraloncology.2012.08.004 – ident: ref23/cit23 doi: 10.1111/jop.13268 – ident: ref48/cit48 doi: 10.1080/1061186X.2018.1502775 – ident: ref26/cit26 doi: 10.1158/1535-7163.MCT-11-0648 – ident: ref24/cit24 doi: 10.1166/jbn.2020.2961 – ident: ref44/cit44 doi: 10.1038/gt.2017.6 – ident: ref50/cit50 doi: 10.1016/j.biomaterials.2018.09.017 – ident: ref7/cit7 doi: 10.1007/s10555-011-9335-7 – ident: ref36/cit36 doi: 10.1002/jgm.3097 – ident: ref25/cit25 doi: 10.1111/cbdd.12993 – ident: ref37/cit37 doi: 10.1039/C7RA13656K – ident: ref20/cit20 doi: 10.1097/CJI.0000000000000166 – ident: ref14/cit14 doi: 10.1186/1471-2407-13-605 – ident: ref11/cit11 doi: 10.1172/JCI125336 – ident: ref28/cit28 doi: 10.2174/0929867328666201207202012 – ident: ref17/cit17 doi: 10.1016/j.bbrc.2015.02.013 – ident: ref27/cit27 doi: 10.1038/nrclinonc.2018.8 – ident: ref47/cit47 doi: 10.3109/1061186X.2015.1070856 – ident: ref30/cit30 doi: 10.1080/14712598.2020.1738377 – ident: ref21/cit21 doi: 10.1016/j.bbrc.2020.11.073 – ident: ref46/cit46 doi: 10.1016/j.jconrel.2012.01.045 – ident: ref43/cit43 doi: 10.1021/acs.nanolett.7b01571 – ident: ref41/cit41 doi: 10.7150/thno.45164 – ident: ref15/cit15 doi: 10.1038/s41556-021-00641-w – ident: ref22/cit22 doi: 10.3390/cancers12071889 – ident: ref29/cit29 doi: 10.2147/IJN.S277845 – ident: ref35/cit35 doi: 10.3892/mmr.2017.7625 – ident: ref45/cit45 doi: 10.1126/sciadv.aay3324 – ident: ref1/cit1 doi: 10.3322/caac.21492 – ident: ref34/cit34 doi: 10.1039/c2nr30079f – ident: ref3/cit3 doi: 10.1016/j.semcancer.2018.01.008 – ident: ref5/cit5 doi: 10.4317/medoral.18772 – ident: ref51/cit51 doi: 10.1016/j.jconrel.2012.05.005 – ident: ref4/cit4 doi: 10.1016/j.ebiom.2019.08.013 – ident: ref13/cit13 doi: 10.1016/j.bone.2008.03.026 – ident: ref16/cit16 doi: 10.1038/s41467-022-31475-1 – ident: ref49/cit49 doi: 10.1002/ijc.33579 |
SSID | ssj0024523 |
Score | 2.4586606 |
Snippet | Oral squamous cell carcinoma (OSCC) accounts for nearly 90% of oral and oropharyngeal cancer cases and is characterized by high mortality and poor prognosis.... |
SourceID | proquest crossref pubmed acs |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 661 |
Title | Systemic and Local Administration of a Dual-siRNA Complex Efficiently Inhibits Tumor Growth and Bone Invasion in Oral Squamous Cell Carcinoma |
URI | http://dx.doi.org/10.1021/acs.molpharmaceut.3c00802 https://www.ncbi.nlm.nih.gov/pubmed/38175819 https://search.proquest.com/docview/2922447438 |
Volume | 21 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSIgL78fy0lRCPTVLYiexcyxLS0FQKrqVeovGjqNG7CawSYDlP_CfGSdZVgtC0GseYyeeyXyZ8XzD2DPNdWJyHXha-8oLTc69BBUSkJOGC5GRRbmM7ruj-PA0fHMWna3ruH_P4PPgOZp6PK9c4ekQ4h0L01WIXmZXuCQjcXhocrIm2Iu6nm4EDYSnhAqvsu1_inKuydSbrukveLPzOwc32HRVvdNvN_k4bhs9Nt__JHO8yCPdZNcHHAp7veLcYpdseZvtHPfXLndhuq7LqndhB47XFNfLO-xHT3ReGMAyg7fOH8ImDS9UOSC8bHHm1cWHoz1wH56Z_Qb7HWcFubrZEl6X54Uumhqm7bxawKtF9bU570S-qEpLp7-gC-ZBUcL7BQ1x8rlFF6qAiZ3NYOLaIJXVHO-y04P96eTQGxo7eChi0XhBnKggN1GAKI1CmVmOfqxkwuMITaIDK4w2Vslcxr60ma8wiHOyZ4z8PBRc3GNbJc3jAQOMIhtL-ivMEEOreWKkFhqtVBmXNMKIkV7W6WCYddrl3HmQuoMbS5AOSzBifKUE6aee8ON_btpeqUtK5ulyLlhaeh8pTwgjhQTT1Ijd7_Xol1hHjhgRInt40Tk-Ytc4KXq3eTx6zLaaRWufEDZq9NPOFn4CGB0QVw |
link.rule.ids | 315,783,787,2772,27088,27936,27937,57070,57120 |
linkProvider | American Chemical Society |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSMCF92N5uhLqqVkSO46dY1latrBdKrqVKvUQjR1HjcgmsEmA5T_wn7GdtKtFQjyuTjKexDOZzx7PZ4ReSCJjlcnAk9IXXqgy4sUgwAA5rgilqfEom9E9mEbj4_DtCTvpd1XaWhijRG0k1S6Jv2IXCF7atnll60_7ld4hVa5Q9DK6wrgxXAuLRkcrnj3mjnYzCIF6gorwKtr8oygboVS9HqF-Aztd-Nm7iU4vFHe7Tj4O20YO1fdfOB3_781uoRs9KsU7nRndRpd0eQdtHXb3LrfxbFWlVW_jLXy4Irxe3kU_OtrzXGEoUzyx0RGvk_LiKsOAX7dQeHX-YbqD7W-o0N_wrmOwMIGvWOL98iyXeVPjWTuvFvjNovranDmRr6pSm8tfwC7t4bzE7xemi6PPLdiFCzzSRYFH9lCksprDPXS8tzsbjb3-mAcPaEQbL4hiEWSKBQBcCeCpJuBHgsckYqBiGWiqpNKCZzzyuU59AUGUGe8G5mchJfQ-2iiNHg8RBsZ0xM0cMQUItSSx4pJK0FykhJseBsiOQNK7aZ24DDwJEtu4NgRJPwQDRM5tIfnU0X_8zUOb51aTGGe1GRgotfkeCYkNYgoNaBMD9KAzpwuxliqRGXz26F91fI6ujWcHk2SyP333GF0nxvbdtnL2BG00i1Y_Naipkc-ce_wEfB0Ytw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwELagSBUv3MeWy5VQn5ptYsex87hsu7RQlhXdSn2Lxo6jRuwm7SYBlv_Af8Z20q4WCXG85hg78Uzmy4znG4ReSyJjlcnAk9IXXqgy4sUgwAA5rgilqbEom9H9MI4OT8N3Z-ysC7jZWhgzicpIqlwS31r1RZp1DAPBnj0-L20Nahft7VPlikVvoluMB8S2bhgMT1Zce8y1dzMogXqCinATbf9RlPVSqlr3Ur-Bns4Fje6i5HrybufJ535Ty776_guv4_8_3T10p0OneNCq0310QxcP0M6kvXa5i6eraq1qF-_gyYr4evkQ_Wjpz3OFoUjxsfWSeJ2cF5cZBrzfwMyr8k_jAbafo5n-hg8ck4VxgLMlPirOc5nXFZ4283KB3y7Kr_W5E_mmLLQ5_QVsiA_nBf64MEOcXDZgAxh4qGczPLTNkYpyDo_Q6ehgOjz0unYPHtCI1l4QxSLIFAsAuBLAU03AjwSPScRAxTLQVEmlBc945HOd-gKCKDNWDszPQkroY7RRmHk8RRgY0xE3_4opQKgliRWXVILmIiXcjNBDdhWSzlyrxGXiSZDYg2tLkHRL0EPkSh-Si5YG5G9u2r7SnMQYrc3EQKHN-0hIbJBTaMCb6KEnrUpdi7WUiczgtK1_neMrtDnZHyXHR-P3z9BtYtTf7S5nz9FGvWj0CwOeavnSWchPN94bMQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Systemic+and+Local+Administration+of+a+Dual-siRNA+Complex+Efficiently+Inhibits+Tumor+Growth+and+Bone+Invasion+in+Oral+Squamous+Cell+Carcinoma&rft.jtitle=Molecular+pharmaceutics&rft.au=Ma%2C+Pingchuan&rft.au=He%2C+Mingxia&rft.au=Lian%2C+Haosen&rft.au=Li%2C+Jingmei&rft.date=2024-02-05&rft.issn=1543-8384&rft.eissn=1543-8392&rft.volume=21&rft.issue=2&rft.spage=661&rft.epage=676&rft_id=info:doi/10.1021%2Facs.molpharmaceut.3c00802&rft.externalDBID=n%2Fa&rft.externalDocID=10_1021_acs_molpharmaceut_3c00802 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1543-8384&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1543-8384&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1543-8384&client=summon |